Kartal

Researchers are studying the use of LSALT peptide to prevent or reduce acute kidney injury AKI in patients undergoing on-pump cardiac surgery. This trial evaluates how often AKI occurs within 7 days after such surgery, using established kidney function criteria. The study is a randomized, double-blind, placebo-controlled Phase 2 trial involving patients at risk of AKI due to their kidney function or other health factors. Participants will be randomly assigned to receive either the LSALT peptide or a placebo. The LSALT peptide is given intravenously at 10 mg over one hour twice daily for five days, starting at least one hour before anesthesia begins. The placebo group receives a matching saline solution on the same schedule. Standard care continues alongside the study treatments, and safety is closely monitored by an independent board. Throughout the study, participants will have daily physical exams, vital sign checks, and urine output monitoring during the treatment period and shortly after. Kidney function tests and biomarker assessments occur at baseline and regularly through 28 days after surgery. Adverse events are recorded daily during treatment and on follow-up days. The study tracks kidney injury severity, need for kidney replacement therapy, mortality, hospital stay length, and other health outcomes to understand the treatments effects.

Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.

Researchers are evaluating the Turkish version of the Barriers to Being Active Quiz BBAQ-T, a tool originally developed in English to identify barriers to physical activity. This study aims to translate and culturally adapt the BBAQ into Turkish and assess its reliability and validity among healthy adults. A total of 210 participants will be involved, mainly healthy university students aged 18 to 35 years. The study follows a standardized translation and back-translation method using bilingual translators. After a pilot study with 15 participants to check clarity and relevance, the full group will complete the BBAQ-T twice within 5 to 7 days to evaluate test-retest reliability. Researchers will analyze internal consistency and compare the BBAQ-T with related questionnaires, including the Self-Perceived Barriers for Physical Activity Questionnaire and the Short Form-12 SF-12. Participants will complete questionnaires assessing barriers to physical activity and related health concepts at baseline and a second time within a week. The study measures how consistent and valid the Turkish version of the quiz is by comparing results from different assessments. This observational study will last from May 20, 2025, to August 20, 2025, involving healthy adults who can read and write in Turkish and do not have conditions that might affect participation.